Form 4: Cytosorbents CFO Boosts Equity Holdings

Cytosorbents' Chief Financial Officer, Peter J. Mariani, acquired 71,500 restricted stock units and 90,000 stock options, increasing his beneficial ownership.

Summary

• Chief Financial Officer Peter J. Mariani of Cytosorbents Corp. acquired 71,500 Restricted Stock Units (RSUs) and 90,000 stock options.
• The 71,500 RSUs were granted at a price of $0 and are scheduled to vest in equal parts on the first and second year anniversaries of the grant date (August 8, 2025), contingent on continued service.
• The 90,000 stock options have an exercise price of $1 and will expire on August 8, 2035. These options vest over three years: 50% on the first anniversary, 25% on the second, and 25% on the third anniversary of the grant date, subject to continued service.
• Following these transactions, Mr. Mariani beneficially owns a total of 538,113 shares of Common Stock and 90,000 stock options.
• The 538,113 shares of Common Stock include 116,613 directly owned shares and various previously granted RSUs with different vesting conditions, such as upon a 'Change In Control' or specific anniversaries (e.g., August 14, 2028 for 110,000 RSUs).

Sentiment

Score: 7

Explanation: The filing indicates an increase in the Chief Financial Officer's beneficial ownership through equity grants, which generally signals management's confidence and aligns their interests with long-term shareholder value.

Positives

• Increased equity alignment between management and shareholders through significant RSU and stock option grants.
• The grants incentivize long-term service and performance, with vesting periods extending up to three years for options and four years for some RSUs, demonstrating a commitment to the company's future.

Future Outlook

The vesting schedules for the newly acquired RSUs and stock options indicate future equity accumulation for the CFO, contingent on continued service. Some previously granted RSUs also have future vesting dates or are tied to a potential Change In Control event, aligning management's long-term incentives with company performance.

Industry Context

Executive equity grants, such as restricted stock units and stock options, are standard practices in the biotechnology and pharmaceutical industries to align management incentives with long-term shareholder value creation and to retain key talent. This filing reflects a typical component of executive compensation within the sector.

Stakeholder Impact

• Shareholders: Increased alignment of management interests with shareholder value through equity incentives, potentially fostering long-term growth.
• Management: The Chief Financial Officer's compensation package is enhanced, incentivizing continued commitment and performance.

Next Steps

• Vesting of 71,500 RSUs on the first and second anniversaries of August 8, 2025.
• Vesting of 90,000 stock options over the first, second, and third anniversaries of August 8, 2025.
• Potential vesting of 110,000 and 175,000 previously granted RSUs upon a 'Change In Control' of Cytosorbents Corporation.
• Vesting of 110,000 previously granted RSUs by August 14, 2028, if no 'Change In Control' occurs earlier.
• Vesting of 65,000 previously granted RSUs on the first and second anniversaries of their grant date.

Key Dates

Recommendation

The acquisition of significant equity grants by the Chief Financial Officer is a positive signal, indicating management's commitment and alignment with long-term company performance. While this specific filing doesn't provide broader financial results, the insider's increased stake suggests confidence. Investors should hold their position and monitor future operational and financial reports for a comprehensive view.

Keywords

Cytosorbents, CTSO, SEC Form 4, Insider Trading, Restricted Stock Units, Stock Options, Executive Compensation, Peter J. Mariani